Oral Squamous Cell Carcinoma Clinical Trial
— OSCCOfficial title:
Comparison of Morphometric Assessment Using Methyl Green Pyronin and AgNOR Staining of Oral Squamous Cell Carcinoma
Oral cancer represents the sixth most common cancer worldwide whilst in Pakistan it ranks
the second most common cancer in either gender. Histologically, over 90% of oral cancer
lesions are squamous cell carcinomas which are diagnosed on the basis of histopathological
analysis. However, proliferation kinetics and nucleolar status are not clearly delineated by
routine H&E examination; thus making use of various proliferation markers imperative for the
purpose.
Nuclear organizer regions (AgNORs) are associated with proliferative activity and represents
as a diagnostic aid in oral malignancies. Similarly, methyl green pyronin (MGP) stain has
also been valuable as a complement in routine histopathological studies of several
neoplastic entities.
Morphometric techniques offer an opportunity to quantify nuclear changes associated with
malignancy and may provide an objective basis for grading the tumors. The present study is
planned to analyze the morphometric parameters of the MGP stain in oral squamous cell
carcinoma, and in their various histological grades, and to assess if the MGP staining
parameters could give information on the aggressiveness of the malignant lesions of oral
cavity.
Sections from thirty cases of squamous cell carcinoma along with thirty cases of normal oral
mucosa will be evaluated for methyl green pyronin (MGP) and AgNOR staining. Morphometric
analysis of various MGP staining and AgNOR parameters would be performed using micrometer.
Statistical analysis of the results will be carried out using SPSS. Quantitative variables
will be expressed as mean ± Standard Deviation. Frequencies and percentages will be given
for qualitative variables.
It is hypothesized that oral squamous cell carcinoma will exhibit significantly higher MGP
staining and AgNOR staining parameters than normal mucosa of the oral cavity.
Status | Enrolling by invitation |
Enrollment | 60 |
Est. completion date | December 2013 |
Est. primary completion date | November 2013 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Specimens of normal epithelium from healthy adult individuals irrespective of age and without habits that predispose to oral cancer - Cases of clinically and histologically confirmed primary oral squamous cell carcinoma based on WHO criteria Exclusion Criteria: - Subjects of oral squamous cell carcinoma with any treatment therapy other than surgical excision. - Subjects having metastatic tumors and tumors other than in the oral cavity - Subjects having recurrent tumors. - Subjects of normal or control group with history of risk / predisposing factors for oral cancer. |
Observational Model: Case Control, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Pakistan | Post Graduate Medical Institute | Lahore | Punjab |
Lead Sponsor | Collaborator |
---|---|
Academy of Interdisciplinary Dental Education and Research | Post Graduate Medical Institute, Lahore, Pakistan |
Pakistan,
Mohtasham N, Mahdavi-Shahri N, Salehinejad J, Ejtehadi H, Torabi-Parizi M, Ghazi N. Detection of nucleoproteins in squamous cell carcinoma, and dysplastic and normal mucosa in the oral cavity by methyl green-pyronin staining. J Oral Sci. 2010 Jun;52(2):239-43. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean values of diameter, area and number of nuclei and nucleoli. | Morphometric parameters including diameter,area and number of nuclei and nucleoli will be determined using AgNOR and Methyl Green Pyronin staining methods. | Within one week of staining of slides | No |
Secondary | Association of grading of OSCC in relation to morphometric parameters | Chi-square test or Fisher exact test will be applied to see any statistical association of grading of OSCC in relation to morphometric parameters. | Within two weeks of staining of slides | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04543266 -
Predicting Metastatic Oral Squamous Cell Carcinomas With Molecular Biomarkers Using Machine Learning
|
||
Not yet recruiting |
NCT06438939 -
NBI for Early Diagnosis of OPMD/OSCC
|
N/A | |
Recruiting |
NCT05024383 -
Dissecting the Heterogeneity of Oral Cancer Pain
|
N/A | |
Recruiting |
NCT06031337 -
Salivary Expression of SOX7 in Oral Squamous Cell Carcinoma: Diagnostic Accuracy Study
|
||
Not yet recruiting |
NCT06174428 -
Validity of Viome's Oral/Throat Cancer Test
|
||
Recruiting |
NCT05098119 -
Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002)
|
Phase 2 | |
Recruiting |
NCT05069857 -
Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients
|
Phase 2 | |
Not yet recruiting |
NCT03619304 -
Assessment of Anti-cancerous Effect of Green, Roasted and Decaffeinated Coffee on Oral Squamous Cell Carcinoma Cell Line
|
N/A | |
Active, not recruiting |
NCT01772706 -
Laser Mucite ORL : Effectiveness of Laser Therapy for Mucositis Induced by a Radio-chemotherapy in Head and Neck Cancer
|
N/A | |
Recruiting |
NCT05893888 -
Safety and Efficacy Study of PRV211 in Subjects With Oral Squamous Cell Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05125055 -
Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06055868 -
People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity
|
||
Not yet recruiting |
NCT06130007 -
A Prospective, Single-arm Phase II Clinical Trial of Tislelizumab Combined With Platinum Doublet Neoadjuvant Therapy to Improve Mandibular Preservation in Resectable Locally Advanced Oral Squamous Cell Carcinoma.
|
Phase 2 | |
Recruiting |
NCT05798793 -
Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma
|
Phase 3 | |
Recruiting |
NCT02739204 -
Concurrent Radiotherapy and/or Cisplatin With or Without Celecoxib in Patients With Primary Oral Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT05708209 -
The Long Non Coding MALAT1 as a Potential Salivary Diagnostic Biomarker in Oral Squamous Cell Carcinoma Through Targeting mi RNA 124
|
||
Recruiting |
NCT05862168 -
Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma :A Single-arm, Prospective, Phase II Trial
|
Phase 2 | |
Recruiting |
NCT05451303 -
Detection of Oral and Throat Cancers Using OralViome Cancer Testing System
|
||
Recruiting |
NCT05902455 -
Differential Mobility Spectrometry (DMS) Based Oral Tumor Analysis
|
||
Not yet recruiting |
NCT05803915 -
Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy
|
Phase 2 |